Is there a sweet spot for nrf2 activation in the treatment of diabetic kidney disease?

Diabetes

Volumn 63, Issue 9, 2014, Pages 2904-2905

  Hall, Evan T ^a   Bhalla, Vivek ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARDOXOLONE METHYL; KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2; UBIQUITIN PROTEIN LIGASE;

ALBUMINURIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE TITRATION; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; NOTE; PRIORITY JOURNAL; RENAL DIABETES; RENAL REPLACEMENT THERAPY; TRANSCRIPTION INITIATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ATHEROSCLEROSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; MALE; OLEANOLIC ACID;

EID: 84906712847     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0829     Document Type: Note

References (12)

1. U.S. Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013
2. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532-2539
3. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012;60:850-886
4. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007;47:89-116
5. Tan SM, Sharma A, Stefanovic N, et al. Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-Associated atherosclerosis and improves diabetic kidney disease. Diabetes 2014;63:3091-3103
6. Dinkova-Kostova AT, Liby KT, Stephenson KK, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 2005;102:4584-4589
7. Pergola PE, Raskin P, Toto RD, et al.; BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365:327-336
8. de Zeeuw D, Akizawa T, Audhya P, et al.; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013;369:2492-2503
9. Himmelfarb J, Tuttle KR. New therapies for diabetic kidney disease. N Engl J Med 2013;369:2549-2550
10. Reisman SA, Chertow GM, Hebbar S, Vaziri ND, Ward KW, Meyer CJ. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. J Am Soc Nephrol 2012;23:1663-1673
11. Zoja C, Corna D, Nava V, et al. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol 2013;304:F808-F819
12. Chin M, Lee CY, Chuang JC, et al. Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity. Am J Physiol Renal Physiol 2013;304:F1438-F1446